Compare PATH & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PATH | ERAS |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.3B |
| IPO Year | 2021 | 2021 |
| Metric | PATH | ERAS |
|---|---|---|
| Price | $12.39 | $13.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 20 | 9 |
| Target Price | $15.41 | ★ $24.11 |
| AVG Volume (30 Days) | ★ 22.4M | 4.8M |
| Earning Date | 12-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 500.00 | 36.23 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,610,572,000.00 | N/A |
| Revenue This Year | $11.28 | N/A |
| Revenue Next Year | $8.25 | N/A |
| P/E Ratio | $119.55 | ★ N/A |
| Revenue Growth | ★ 12.65 | N/A |
| 52 Week Low | $9.20 | $2.75 |
| 52 Week High | $19.84 | $24.28 |
| Indicator | PATH | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 39.17 | 43.56 |
| Support Level | $10.58 | $13.18 |
| Resistance Level | $13.33 | $15.71 |
| Average True Range (ATR) | 0.49 | 1.31 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 8.92 | 18.09 |
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies, including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries, including claims processing, employee onboarding, invoice-to-cash, loan applications, and customer service. The company works in the Americas, Europe, the Middle East, and Africa, and Asia-Pacific, with the maximum revenue from the America.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.